Bridging pre-surgical endocrine therapy for breast cancer during the COVID-19 pandemic: outcomes from the B-MaP-C study.
Dave RV, Elsberger B, Taxiarchi VP, Gandhi A, Kirwan CC, Kim B, Camacho EM, Coles CE, Copson E, Courtney A, Horgan K, Fairbrother P, Holcombe C, Kirkham JJ, Leff DR, McIntosh SA, O'Connell R, Pardo R, Potter S, Rattay T, Sharma N, Vidya R, Cutress RI; B-MaP-C study collaborative.
Dave RV, et al.
Breast Cancer Res Treat. 2023 Jun;199(2):265-279. doi: 10.1007/s10549-023-06893-4. Epub 2023 Apr 3.
Breast Cancer Res Treat. 2023.
PMID: 37010651
Free PMC article.
BrET was found to be tolerable and safe. The data support short-term ( 3 months) usage of pre-operative endocrine therapy. Longer-term use should be investigated in future trials....
BrET was found to be tolerable and safe. The data support short-term ( 3 months) usage of pre-operative endocrine therapy. Longer- …